TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cmax of PF-06260414 formulations under fed condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of PF-06260414 formulations under fed condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of E5501
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCss of E5501
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet counts for E5501
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cmax of E5501
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of CTC grade 3 and 4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Sensory assessment of the children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor proficiency of the children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cortical synaptic plasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic performance of AminoIndex™
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quantity of newly-formed bone tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 5-year loco-regional recurrence free survival
Endpoint domain: Mortality/survival
Primary endpoint: quality of recovery at discharge
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: quality of recovery post operatively
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Omentin-1 serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification Rate for Feasibility of ARM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Combined Safety-Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of detection of new syphilis cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent of Participants With Primary Safety Endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Change in maximum diameter of the lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of exacerbation during the COVID-19 epidemic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cerebral and mesenteric oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Morbidity of primary open-angle glaucoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain interference
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete steroid reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pdi evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pupillary Reflex Dilation (PRD) Area under Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in outcomes from scan 1 to scan 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in hepatocyte injury and fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percentage of Participants Wearing Helmet
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emax - Maximum Inhibition of COMT Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Neutrophil Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: body mass change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of patients that present metastasis when consulting for first time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of success in first-line treatment with Sutent, in first-line treatment with IFN-α and in first-line treatment with Bevacizumab + IFN-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization average with Sutent, with IFN-α, and with Bevacizumab + IFN-α
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Postprandial nitrotyrosine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of treatment-emergent serious adverse events (TE-SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in inactivation of influenza virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of atlantoaxial joint affection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Level of IFN-gamma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anterior teeth retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of osteoprotegerin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of breath test for early oesophageal cancer and Barrett's high grade dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Newcastle Mitochondrial Disease Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vancouver Scar Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in the Patient Safety Climate Synthetic Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sustained Virologic Response 12 Weeks After Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Experiencing at Least One Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinued From Study Therapy Due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: current level of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percentage time-in-hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients With Renal Allograft Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rejection Day of Onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rise in Serum Creatineine Above Posttransplant Nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety and tolerability of intra articular injection
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery of malnourished patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modelled C0/morning trough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ (area under the concentration time curve of BILR 355 in plasma over one dosing interval at steady state)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (maximum concentration of BILR 355 in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Normalized Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuro-cognitive development of children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Participants Preference for Nasal Spray
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time-to-first Severe Asthma Exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Severe Asthma Exacerbation
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline Jamar Test at 3th week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Jebsen Taylor Hand Function Test (JTHFT) at 3th week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Patient Rated Wrist/Hand Evaluation (PRWE) at 3th week
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Change From Baseline in Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Equivalency of isoforms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utilization of care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: SUV values of GD patients and normal humans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritation
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative dental pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Reactions of the Injection Site
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Any Abnormal Findings From Physical Examinations After Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Clinically Significant Laboratory Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from Baseline in Dietary habits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from Baseline in BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacodynamics assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events following thymus transplantation
Endpoint domain: Adverse events/effects
Primary endpoint: delay between intensive care admission and antibiotic initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delta respiratory SOFA score between Day 1 and day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gingival crevicular fluid CypA total amounts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in gingival crevicular fluid EMMPRIN total amounts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oxygen absorption during stress test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient HRQOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean change in ETDRS BCVA visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: altered OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the plasma concentration versus time Curve (AUC)last
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Integrated gastric acidity for 24-hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of abnormal nailfold capillaroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve GIR(0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GIRMax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC Lisp(0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax(Lisp)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of complete remissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Best Biochemical Response (CA-125)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ablation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of Vertical Height of Buccal Defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle microcirculation during submaximal exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR Efficacy Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disabilities of arm shoulder and hand
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: BCR-ABL transcript levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Critical flicker fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with intervention-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage change of UACR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage change of Creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage change of eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Asthma Control Test (ACT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Urgent Health Utilization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Frequency of Asthma-related Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Changes from baseline in Blood Pressure / Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes from baseline in ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of Participants With Desired Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in step length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of change in rheumatoid arthritis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of major cardiac events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Evaluation of healing timing in myocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of the incidence of major cardiac events in different patient subgroups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of aphasia
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of AGE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hyperlactatemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Predictive value of TS expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Psychometric properties of the French version of the PSQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Flexibility Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability Level Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Equivalence of IB10 sphingotest PCT+ measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Precision of IB10 sphingotest PCT+ measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In vitro stability of procalcitonin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of healthy volunteers reported with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Concentration (C max) of Trappsol in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Concentration (T max) of Trappsol in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half-life (T1/2) of Trappsol in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway microbiome evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective pathological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion Enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: flow propagational velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: E-velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: A-velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of asystole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vitamin D intake optimization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in supraspinatus muscle atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of FIBTEM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MADRS Total Score Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and Severity of Toxicity Incidents
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Symptomatic Venous Thromboembolic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Major Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with serious and non-serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in pulmonary function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum concentrations of pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: significant prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Evaluation of patients with Acute Coronary Syndromes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in lower body muscular power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Aerobic fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average time of polyp removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of dysregulated cardiometabolic risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in levels of adipose risk factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in levels of blood pressure risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in levels of metabolic risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subjective health effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response rate of final overall evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean value of the maximum observed concentration (Cmax) postdose of perampanel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean value for area under the concentration-time curve from zero time to 24 hours (AUC[0-24h]) postdose of perampanel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean value for terminal elimination phase half-life (t1/2) postdose of perampanel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to hemopoietic recovery after transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of the Philadelphia chromosome or the BCR/ABL gene abnormality in post-transplantation marrow samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Shock Index (SI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Age-adjusted Shock Index (aSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic Shock Index (dSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: modified Shock Index (mSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of Days of Confirmed Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hamstring Peak Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes